These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27362901)

  • 61. [An ovarian mucinous borderline tumour with mixed mural nodules].
    Dhouibi A; Denoux Y; Touil N; Devouassoux Shisheboran M; Carbonnel M; Baglin AC
    J Gynecol Obstet Biol Reprod (Paris); 2011 Sep; 40(5):469-72. PubMed ID: 21531088
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
    Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Intestinal type borderline mucinous ovarian tumour.
    Shakya B
    J Nepal Health Res Counc; 2014 Jan; 12(26):68-9. PubMed ID: 25574989
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pseudomyxoma peritonei associated with ovarian mucinous tumors. Cytologic appearance in five cases.
    Leiman G; Goldberg R
    Acta Cytol; 1992; 36(3):299-304. PubMed ID: 1316027
    [TBL] [Abstract][Full Text] [Related]  

  • 65. P53 and Ki67 immunoexpression in mucinous malignant ovarian tumors.
    Kamal CK; Simionescu CE; Mărgăritescu C; Stepan A
    Rom J Morphol Embryol; 2012; 53(3 Suppl):799-803. PubMed ID: 23188443
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Clinico-prognostic factors in cancer of the ovaries].
    Ali-Zade VA; Atakishiev AR
    Vopr Onkol; 1990; 36(8):1005-6. PubMed ID: 2171225
    [No Abstract]   [Full Text] [Related]  

  • 67. [Staging and grading experiences in ovarian carcinoma and their prognostic value].
    Bartl W; Janisch H; Szalay S; Szepesi T; Tatra G; Breitenecker G
    Gynakol Rundsch; 1982; 22(2):158-64. PubMed ID: 6286427
    [No Abstract]   [Full Text] [Related]  

  • 68. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases.
    Aure JC; Hoeg K; Kolstad P
    Obstet Gynecol; 1971 Jan; 37(1):1-9. PubMed ID: 4321469
    [No Abstract]   [Full Text] [Related]  

  • 69. [Degree of differentiation of ovarian cancer and its clinical significance].
    Zagol'skaia VN; Vinokurov VL; Nechaeva ID; Pozharisskiĭ KM; Iurkova LE
    Vopr Onkol; 1985; 31(9):62-70. PubMed ID: 2996225
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Biologic behavior of primary ovarian malignancy.
    Julian CG; Goss J; Blanchard K; Woodruff JD
    Obstet Gynecol; 1974 Dec; 44(6):873-84. PubMed ID: 4373686
    [No Abstract]   [Full Text] [Related]  

  • 71. Histochemical analysis of estrogen and progesterone receptors and gastric-type mucin in mucinous ovarian tumors with reference to their pathogenesis.
    Shiohara S; Shiozawa T; Shimizu M; Toki T; Ishii K; Nikaido T; Fujii S
    Cancer; 1997 Sep; 80(5):908-16. PubMed ID: 9307191
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Endometriosis and ovarian cancer.
    Vercellini P; Parazzini F; Bolis G; Carinelli S; Dindelli M; Vendola N; Luchini L; Crosignani PG
    Am J Obstet Gynecol; 1993 Jul; 169(1):181-2. PubMed ID: 8392791
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ovarian Seromucinous Borderline Tumor and Clear Cell Carcinoma: An Unusual Combination.
    Nakamura E; Sato Y; Moriguchi S; Yamashita A; Higo T; Asada Y
    Case Rep Obstet Gynecol; 2015; 2015():690891. PubMed ID: 26075120
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Association between atypical endometriosis and ovarian malignancies in the real world.
    So KA; Hong SR; Kim NR; Yang EJ; Shim SH; Lee SJ; Kim TJ
    J Ovarian Res; 2021 Aug; 14(1):110. PubMed ID: 34454550
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prognostic variables in epithelial ovarian cancer: a review.
    Friedlander ML
    Aust N Z J Obstet Gynaecol; 1984 Nov; 24(4):256-61. PubMed ID: 6100044
    [No Abstract]   [Full Text] [Related]  

  • 76. Seromucinous and Mucinous Borderline Ovarian Tumors: We Need to Know More.
    Laban M; Chen X; Guo B
    Reprod Sci; 2023 May; 30(5):1684-1685. PubMed ID: 36474132
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Three cases of seromucinous carcinoma of the ovary arising in endometriotic cysts.
    Taga Y; Chigusa Y; Minamiguchi S; Kido A; Horikawa N; Horie A; Hamanishi J; Kondoh E; Mandai M; Yamaguchi K
    Int Cancer Conf J; 2021 Jan; 10(1):46-53. PubMed ID: 33489701
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Molecular genetic profile of seromucinous ovarian tumors].
    Novikov FV; Luneva IS; Starkova OA
    Arkh Patol; 2021; 83(1):53-57. PubMed ID: 33512129
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Peritoneal borderline cystoadenocarcinoma.
    Girão MJ; Sartori MG; Gonçalves WJ; de Lima GR
    Sao Paulo Med J; 1998; 116(1):1634-6. PubMed ID: 9699387
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinicopathologic Features and the Loss of ARID1A Expression in Ovarian Seromucinous Borderline Tumors and Seromucinous Carcinomas.
    Ok Atılgan A; Özen Ö; Haberal Reyhan AN; Ayhan A
    Int J Surg Pathol; 2023 Jun; 31(4):398-408. PubMed ID: 36452965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.